Current smoking status is associated to a non-ACR 50 response in early rheumatoid arthritis. A cohort study
Identifieur interne : 001F05 ( Istex/Corpus ); précédent : 001F04; suivant : 001F06Current smoking status is associated to a non-ACR 50 response in early rheumatoid arthritis. A cohort study
Auteurs : Jorge Rojas-Serrano ; Leticia Lino Pérez ; Conrado García García ; Francisco Moctezuma ; Everardo Álvarez-Hernández ; Janitzia Vázquez-Mellado ; José Luis Montiel ; Rubén Burgos-VargasSource :
- Clinical Rheumatology [ 0770-3198 ] ; 2011-12-01.
English descriptors
- KwdEn :
Abstract
Abstract: The purpose of this study is to determine factors associated with a non-ACR 50 response at 6 months of follow-up, in a cohort of patients with early rheumatoid arthritis (RA). Early RA patients (symptom duration <1 year), treated with the same combination treatment (methotrexate and sulfasalazine), were included. Demographic characteristics of the patients including current smoker status (defined as a patient that smokes at least one cigarette per day), years of formal education, a 28-joint count for swelling and tenderness were registered. A basal HAQ questionnaire, visual scales for global assessment, and pain were answered by all patients, and a CDAI basal score was calculated. The ACR 50 response was determined at 6 months follow-up. Multivariable logistic regression analysis was used to calculate adjusted ORs. Two hundred twenty-five patients were evaluated, but only 144 had a complete follow-up, 43% of the latter did not reach an ACR 50 response. The only factor associated with this outcome was current smoking (OR 3.58, P < 0.008, 95% CI 1.23–11.22). Low level of formal education (≤6 years) had a tendency towards a statistical difference (P < 0.08). After controlling with low level of formal education, sex, age in years, and CDAI baseline value with multivariable logistic regression analysis, current smoking status had an adjusted OR of 3.91 (P < 0.009, 95% CI 1.41–10.81). Smoking is associated with a non-ACR 50 response in early rheumatoid arthritis in patients treated with a combination therapy with methotrexate and sulfasalazine.
Url:
DOI: 10.1007/s10067-011-1775-5
Links to Exploration step
ISTEX:32146B4C9F763382B0127713652689FEEA340BA6Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Current smoking status is associated to a non-ACR 50 response in early rheumatoid arthritis. A cohort study</title><author><name sortKey="Rojas Serrano, Jorge" sort="Rojas Serrano, Jorge" uniqKey="Rojas Serrano J" first="Jorge" last="Rojas-Serrano">Jorge Rojas-Serrano</name><affiliation><mods:affiliation>Instituto Nacional de Enfermedades Respiratorias, Ismael Cosío Villegas, Universidad Nacional Autónoma de México, Faculty of Medicine, Mexico City, Mexico</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: jrojas@iner.gob.mx</mods:affiliation></affiliation></author><author><name sortKey="Perez, Leticia Lino" sort="Perez, Leticia Lino" uniqKey="Perez L" first="Leticia Lino" last="Pérez">Leticia Lino Pérez</name><affiliation><mods:affiliation>Department of Rheumatology, Hospital General de México, Mexico City, Mexico</mods:affiliation></affiliation></author><author><name sortKey="Garcia, Conrado Garcia" sort="Garcia, Conrado Garcia" uniqKey="Garcia C" first="Conrado García" last="García">Conrado García García</name><affiliation><mods:affiliation>Department of Rheumatology, Hospital General de México, Mexico City, Mexico</mods:affiliation></affiliation></author><author><name sortKey="Moctezuma, Francisco" sort="Moctezuma, Francisco" uniqKey="Moctezuma F" first="Francisco" last="Moctezuma">Francisco Moctezuma</name><affiliation><mods:affiliation>Department of Rheumatology, Hospital General de México, Mexico City, Mexico</mods:affiliation></affiliation></author><author><name sortKey="Alvarez Hernandez, Everardo" sort="Alvarez Hernandez, Everardo" uniqKey="Alvarez Hernandez E" first="Everardo" last="Álvarez-Hernández">Everardo Álvarez-Hernández</name><affiliation><mods:affiliation>Department of Rheumatology, Hospital General de México, Mexico City, Mexico</mods:affiliation></affiliation></author><author><name sortKey="Vazquez Mellado, Janitzia" sort="Vazquez Mellado, Janitzia" uniqKey="Vazquez Mellado J" first="Janitzia" last="Vázquez-Mellado">Janitzia Vázquez-Mellado</name><affiliation><mods:affiliation>Department of Rheumatology, Hospital General de México, Mexico City, Mexico</mods:affiliation></affiliation><affiliation><mods:affiliation>Universidad Nacional Autónoma de México, Faculty of Medicine, Mexico City, Mexico</mods:affiliation></affiliation></author><author><name sortKey="Montiel, Jose Luis" sort="Montiel, Jose Luis" uniqKey="Montiel J" first="José Luis" last="Montiel">José Luis Montiel</name><affiliation><mods:affiliation>Universidad Autónoma del Estado de Morelos, Facultad de Farmacia, Mexico City, Mexico</mods:affiliation></affiliation></author><author><name sortKey="Burgos Vargas, Ruben" sort="Burgos Vargas, Ruben" uniqKey="Burgos Vargas R" first="Rubén" last="Burgos-Vargas">Rubén Burgos-Vargas</name><affiliation><mods:affiliation>Department of Rheumatology, Hospital General de México, Mexico City, Mexico</mods:affiliation></affiliation><affiliation><mods:affiliation>Universidad Nacional Autónoma de México, Faculty of Medicine, Mexico City, Mexico</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: burgosv@prodigy.net.mx</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:32146B4C9F763382B0127713652689FEEA340BA6</idno><date when="2011" year="2011">2011</date><idno type="doi">10.1007/s10067-011-1775-5</idno><idno type="url">https://api.istex.fr/ark:/67375/VQC-MVSBSK0P-P/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">001F05</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001F05</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Current smoking status is associated to a non-ACR 50 response in early rheumatoid arthritis. A cohort study</title><author><name sortKey="Rojas Serrano, Jorge" sort="Rojas Serrano, Jorge" uniqKey="Rojas Serrano J" first="Jorge" last="Rojas-Serrano">Jorge Rojas-Serrano</name><affiliation><mods:affiliation>Instituto Nacional de Enfermedades Respiratorias, Ismael Cosío Villegas, Universidad Nacional Autónoma de México, Faculty of Medicine, Mexico City, Mexico</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: jrojas@iner.gob.mx</mods:affiliation></affiliation></author><author><name sortKey="Perez, Leticia Lino" sort="Perez, Leticia Lino" uniqKey="Perez L" first="Leticia Lino" last="Pérez">Leticia Lino Pérez</name><affiliation><mods:affiliation>Department of Rheumatology, Hospital General de México, Mexico City, Mexico</mods:affiliation></affiliation></author><author><name sortKey="Garcia, Conrado Garcia" sort="Garcia, Conrado Garcia" uniqKey="Garcia C" first="Conrado García" last="García">Conrado García García</name><affiliation><mods:affiliation>Department of Rheumatology, Hospital General de México, Mexico City, Mexico</mods:affiliation></affiliation></author><author><name sortKey="Moctezuma, Francisco" sort="Moctezuma, Francisco" uniqKey="Moctezuma F" first="Francisco" last="Moctezuma">Francisco Moctezuma</name><affiliation><mods:affiliation>Department of Rheumatology, Hospital General de México, Mexico City, Mexico</mods:affiliation></affiliation></author><author><name sortKey="Alvarez Hernandez, Everardo" sort="Alvarez Hernandez, Everardo" uniqKey="Alvarez Hernandez E" first="Everardo" last="Álvarez-Hernández">Everardo Álvarez-Hernández</name><affiliation><mods:affiliation>Department of Rheumatology, Hospital General de México, Mexico City, Mexico</mods:affiliation></affiliation></author><author><name sortKey="Vazquez Mellado, Janitzia" sort="Vazquez Mellado, Janitzia" uniqKey="Vazquez Mellado J" first="Janitzia" last="Vázquez-Mellado">Janitzia Vázquez-Mellado</name><affiliation><mods:affiliation>Department of Rheumatology, Hospital General de México, Mexico City, Mexico</mods:affiliation></affiliation><affiliation><mods:affiliation>Universidad Nacional Autónoma de México, Faculty of Medicine, Mexico City, Mexico</mods:affiliation></affiliation></author><author><name sortKey="Montiel, Jose Luis" sort="Montiel, Jose Luis" uniqKey="Montiel J" first="José Luis" last="Montiel">José Luis Montiel</name><affiliation><mods:affiliation>Universidad Autónoma del Estado de Morelos, Facultad de Farmacia, Mexico City, Mexico</mods:affiliation></affiliation></author><author><name sortKey="Burgos Vargas, Ruben" sort="Burgos Vargas, Ruben" uniqKey="Burgos Vargas R" first="Rubén" last="Burgos-Vargas">Rubén Burgos-Vargas</name><affiliation><mods:affiliation>Department of Rheumatology, Hospital General de México, Mexico City, Mexico</mods:affiliation></affiliation><affiliation><mods:affiliation>Universidad Nacional Autónoma de México, Faculty of Medicine, Mexico City, Mexico</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: burgosv@prodigy.net.mx</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Clinical Rheumatology</title><title level="j" type="sub">Journal of the International League of Associations for Rheumatology</title><title level="j" type="abbrev">Clin Rheumatol</title><idno type="ISSN">0770-3198</idno><idno type="eISSN">1434-9949</idno><imprint><publisher>Springer-Verlag</publisher><pubPlace>London</pubPlace><date type="published" when="2011-12-01">2011-12-01</date><biblScope unit="volume">30</biblScope><biblScope unit="issue">12</biblScope><biblScope unit="page" from="1589">1589</biblScope><biblScope unit="page" to="1593">1593</biblScope></imprint><idno type="ISSN">0770-3198</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0770-3198</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Early rheumatoid arthritis</term><term>Methotrexate</term><term>Prognostic factors</term><term>Rheumatoid arthritis</term><term>Sulfasalazine</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Abstract: The purpose of this study is to determine factors associated with a non-ACR 50 response at 6 months of follow-up, in a cohort of patients with early rheumatoid arthritis (RA). Early RA patients (symptom duration <1 year), treated with the same combination treatment (methotrexate and sulfasalazine), were included. Demographic characteristics of the patients including current smoker status (defined as a patient that smokes at least one cigarette per day), years of formal education, a 28-joint count for swelling and tenderness were registered. A basal HAQ questionnaire, visual scales for global assessment, and pain were answered by all patients, and a CDAI basal score was calculated. The ACR 50 response was determined at 6 months follow-up. Multivariable logistic regression analysis was used to calculate adjusted ORs. Two hundred twenty-five patients were evaluated, but only 144 had a complete follow-up, 43% of the latter did not reach an ACR 50 response. The only factor associated with this outcome was current smoking (OR 3.58, P < 0.008, 95% CI 1.23–11.22). Low level of formal education (≤6 years) had a tendency towards a statistical difference (P < 0.08). After controlling with low level of formal education, sex, age in years, and CDAI baseline value with multivariable logistic regression analysis, current smoking status had an adjusted OR of 3.91 (P < 0.009, 95% CI 1.41–10.81). Smoking is associated with a non-ACR 50 response in early rheumatoid arthritis in patients treated with a combination therapy with methotrexate and sulfasalazine.</div></front></TEI><istex><corpusName>springer-journals</corpusName><author><json:item><name>Jorge Rojas-Serrano</name><affiliations><json:string>Instituto Nacional de Enfermedades Respiratorias, Ismael Cosío Villegas, Universidad Nacional Autónoma de México, Faculty of Medicine, Mexico City, Mexico</json:string><json:string>E-mail: jrojas@iner.gob.mx</json:string></affiliations></json:item><json:item><name>Leticia Lino Pérez</name><affiliations><json:string>Department of Rheumatology, Hospital General de México, Mexico City, Mexico</json:string></affiliations></json:item><json:item><name>Conrado García García</name><affiliations><json:string>Department of Rheumatology, Hospital General de México, Mexico City, Mexico</json:string></affiliations></json:item><json:item><name>Francisco Moctezuma</name><affiliations><json:string>Department of Rheumatology, Hospital General de México, Mexico City, Mexico</json:string></affiliations></json:item><json:item><name>Everardo Álvarez-Hernández</name><affiliations><json:string>Department of Rheumatology, Hospital General de México, Mexico City, Mexico</json:string></affiliations></json:item><json:item><name>Janitzia Vázquez-Mellado</name><affiliations><json:string>Department of Rheumatology, Hospital General de México, Mexico City, Mexico</json:string><json:string>Universidad Nacional Autónoma de México, Faculty of Medicine, Mexico City, Mexico</json:string></affiliations></json:item><json:item><name>José Luis Montiel</name><affiliations><json:string>Universidad Autónoma del Estado de Morelos, Facultad de Farmacia, Mexico City, Mexico</json:string></affiliations></json:item><json:item><name>Rubén Burgos-Vargas</name><affiliations><json:string>Department of Rheumatology, Hospital General de México, Mexico City, Mexico</json:string><json:string>Universidad Nacional Autónoma de México, Faculty of Medicine, Mexico City, Mexico</json:string><json:string>E-mail: burgosv@prodigy.net.mx</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Early rheumatoid arthritis</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Methotrexate</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Prognostic factors</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Rheumatoid arthritis</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Sulfasalazine</value></json:item></subject><articleId><json:string>1775</json:string><json:string>s10067-011-1775-5</json:string></articleId><arkIstex>ark:/67375/VQC-MVSBSK0P-P</arkIstex><language><json:string>eng</json:string></language><originalGenre><json:string>OriginalPaper</json:string></originalGenre><abstract>Abstract: The purpose of this study is to determine factors associated with a non-ACR 50 response at 6 months of follow-up, in a cohort of patients with early rheumatoid arthritis (RA). Early RA patients (symptom duration >1 year), treated with the same combination treatment (methotrexate and sulfasalazine), were included. Demographic characteristics of the patients including current smoker status (defined as a patient that smokes at least one cigarette per day), years of formal education, a 28-joint count for swelling and tenderness were registered. A basal HAQ questionnaire, visual scales for global assessment, and pain were answered by all patients, and a CDAI basal score was calculated. The ACR 50 response was determined at 6 months follow-up. Multivariable logistic regression analysis was used to calculate adjusted ORs. Two hundred twenty-five patients were evaluated, but only 144 had a complete follow-up, 43% of the latter did not reach an ACR 50 response. The only factor associated with this outcome was current smoking (OR 3.58, P > 0.008, 95% CI 1.23–11.22). Low level of formal education (≤6 years) had a tendency towards a statistical difference (P > 0.08). After controlling with low level of formal education, sex, age in years, and CDAI baseline value with multivariable logistic regression analysis, current smoking status had an adjusted OR of 3.91 (P > 0.009, 95% CI 1.41–10.81). Smoking is associated with a non-ACR 50 response in early rheumatoid arthritis in patients treated with a combination therapy with methotrexate and sulfasalazine.</abstract><qualityIndicators><score>7.652</score><pdfWordCount>2844</pdfWordCount><pdfCharCount>18654</pdfCharCount><pdfVersion>1.4</pdfVersion><pdfPageCount>5</pdfPageCount><pdfPageSize>595.276 x 790.866 pts</pdfPageSize><refBibsNative>false</refBibsNative><abstractWordCount>234</abstractWordCount><abstractCharCount>1574</abstractCharCount><keywordCount>5</keywordCount></qualityIndicators><title>Current smoking status is associated to a non-ACR 50 response in early rheumatoid arthritis. A cohort study</title><genre><json:string>research-article</json:string></genre><host><title>Clinical Rheumatology</title><language><json:string>unknown</json:string></language><publicationDate>2011</publicationDate><copyrightDate>2011</copyrightDate><issn><json:string>0770-3198</json:string></issn><eissn><json:string>1434-9949</json:string></eissn><journalId><json:string>10067</json:string></journalId><volume>30</volume><issue>12</issue><pages><first>1589</first><last>1593</last></pages><genre><json:string>journal</json:string></genre><subject><json:item><value>Rheumatology</value></json:item></subject></host><ark><json:string>ark:/67375/VQC-MVSBSK0P-P</json:string></ark><publicationDate>2011</publicationDate><copyrightDate>2011</copyrightDate><doi><json:string>10.1007/s10067-011-1775-5</json:string></doi><id>32146B4C9F763382B0127713652689FEEA340BA6</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/ark:/67375/VQC-MVSBSK0P-P/fulltext.pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/ark:/67375/VQC-MVSBSK0P-P/bundle.zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/ark:/67375/VQC-MVSBSK0P-P/fulltext.tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Current smoking status is associated to a non-ACR 50 response in early rheumatoid arthritis. A cohort study</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher scheme="https://scientific-publisher.data.istex.fr">Springer-Verlag</publisher><pubPlace>London</pubPlace><availability><licence><p>Clinical Rheumatology, 2011</p></licence><p scheme="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-3XSW68JL-F">springer</p></availability><date>2010-09-10</date></publicationStmt><notesStmt><note type="research-article" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-1JC4F85T-7">research-article</note><note type="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note><note>Original Article</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Current smoking status is associated to a non-ACR 50 response in early rheumatoid arthritis. A cohort study</title><author xml:id="author-0000"><persName><forename type="first">Jorge</forename><surname>Rojas-Serrano</surname></persName><email>jrojas@iner.gob.mx</email><affiliation>Instituto Nacional de Enfermedades Respiratorias, Ismael Cosío Villegas, Universidad Nacional Autónoma de México, Faculty of Medicine, Mexico City, Mexico</affiliation></author><author xml:id="author-0001"><persName><forename type="first">Leticia</forename><surname>Pérez</surname></persName><affiliation>Department of Rheumatology, Hospital General de México, Mexico City, Mexico</affiliation></author><author xml:id="author-0002"><persName><forename type="first">Conrado</forename><surname>García</surname></persName><affiliation>Department of Rheumatology, Hospital General de México, Mexico City, Mexico</affiliation></author><author xml:id="author-0003"><persName><forename type="first">Francisco</forename><surname>Moctezuma</surname></persName><affiliation>Department of Rheumatology, Hospital General de México, Mexico City, Mexico</affiliation></author><author xml:id="author-0004"><persName><forename type="first">Everardo</forename><surname>Álvarez-Hernández</surname></persName><affiliation>Department of Rheumatology, Hospital General de México, Mexico City, Mexico</affiliation></author><author xml:id="author-0005"><persName><forename type="first">Janitzia</forename><surname>Vázquez-Mellado</surname></persName><affiliation>Department of Rheumatology, Hospital General de México, Mexico City, Mexico</affiliation><affiliation>Universidad Nacional Autónoma de México, Faculty of Medicine, Mexico City, Mexico</affiliation></author><author xml:id="author-0006"><persName><forename type="first">José</forename><surname>Montiel</surname></persName><affiliation>Universidad Autónoma del Estado de Morelos, Facultad de Farmacia, Mexico City, Mexico</affiliation></author><author xml:id="author-0007" corresp="yes"><persName><forename type="first">Rubén</forename><surname>Burgos-Vargas</surname></persName><email>burgosv@prodigy.net.mx</email><affiliation>Department of Rheumatology, Hospital General de México, Mexico City, Mexico</affiliation><affiliation>Universidad Nacional Autónoma de México, Faculty of Medicine, Mexico City, Mexico</affiliation></author><idno type="istex">32146B4C9F763382B0127713652689FEEA340BA6</idno><idno type="ark">ark:/67375/VQC-MVSBSK0P-P</idno><idno type="DOI">10.1007/s10067-011-1775-5</idno><idno type="article-id">1775</idno><idno type="article-id">s10067-011-1775-5</idno></analytic><monogr><title level="j">Clinical Rheumatology</title><title level="j" type="sub">Journal of the International League of Associations for Rheumatology</title><title level="j" type="abbrev">Clin Rheumatol</title><idno type="pISSN">0770-3198</idno><idno type="eISSN">1434-9949</idno><idno type="journal-ID">true</idno><idno type="issue-article-count">18</idno><idno type="volume-issue-count">12</idno><imprint><publisher>Springer-Verlag</publisher><pubPlace>London</pubPlace><date type="published" when="2011-12-01"></date><biblScope unit="volume">30</biblScope><biblScope unit="issue">12</biblScope><biblScope unit="page" from="1589">1589</biblScope><biblScope unit="page" to="1593">1593</biblScope></imprint></monogr></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2010-09-10</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Abstract: The purpose of this study is to determine factors associated with a non-ACR 50 response at 6 months of follow-up, in a cohort of patients with early rheumatoid arthritis (RA). Early RA patients (symptom duration <1 year), treated with the same combination treatment (methotrexate and sulfasalazine), were included. Demographic characteristics of the patients including current smoker status (defined as a patient that smokes at least one cigarette per day), years of formal education, a 28-joint count for swelling and tenderness were registered. A basal HAQ questionnaire, visual scales for global assessment, and pain were answered by all patients, and a CDAI basal score was calculated. The ACR 50 response was determined at 6 months follow-up. Multivariable logistic regression analysis was used to calculate adjusted ORs. Two hundred twenty-five patients were evaluated, but only 144 had a complete follow-up, 43% of the latter did not reach an ACR 50 response. The only factor associated with this outcome was current smoking (OR 3.58, P < 0.008, 95% CI 1.23–11.22). Low level of formal education (≤6 years) had a tendency towards a statistical difference (P < 0.08). After controlling with low level of formal education, sex, age in years, and CDAI baseline value with multivariable logistic regression analysis, current smoking status had an adjusted OR of 3.91 (P < 0.009, 95% CI 1.41–10.81). Smoking is associated with a non-ACR 50 response in early rheumatoid arthritis in patients treated with a combination therapy with methotrexate and sulfasalazine.</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>Early rheumatoid arthritis</term></item><item><term>Methotrexate</term></item><item><term>Prognostic factors</term></item><item><term>Rheumatoid arthritis</term></item><item><term>Sulfasalazine</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>Medicine & Public Health</head><item><term>Rheumatology</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2010-09-10">Created</change><change when="2011-12-01">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/ark:/67375/VQC-MVSBSK0P-P/fulltext.txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="corpus springer-journals not found" wicri:toSee="no header"><istex:xmlDeclaration>version="1.0" encoding="UTF-8"</istex:xmlDeclaration><istex:docType PUBLIC="-//Springer-Verlag//DTD A++ V2.4//EN" URI="http://devel.springer.de/A++/V2.4/DTD/A++V2.4.dtd" name="istex:docType"></istex:docType><istex:document><Publisher><PublisherInfo><PublisherName>Springer-Verlag</PublisherName><PublisherLocation>London</PublisherLocation></PublisherInfo><Journal OutputMedium="All"><JournalInfo JournalProductType="ArchiveJournal" NumberingStyle="Unnumbered"><JournalID>10067</JournalID><JournalPrintISSN>0770-3198</JournalPrintISSN><JournalElectronicISSN>1434-9949</JournalElectronicISSN><JournalTitle>Clinical Rheumatology</JournalTitle><JournalSubTitle>Journal of the International League of Associations for Rheumatology</JournalSubTitle><JournalAbbreviatedTitle>Clin Rheumatol</JournalAbbreviatedTitle><JournalSubjectGroup><JournalSubject Type="Primary">Medicine & Public Health</JournalSubject><JournalSubject Type="Secondary">Rheumatology</JournalSubject></JournalSubjectGroup></JournalInfo><Volume OutputMedium="All"><VolumeInfo TocLevels="0" VolumeType="Regular"><VolumeIDStart>30</VolumeIDStart><VolumeIDEnd>30</VolumeIDEnd><VolumeIssueCount>12</VolumeIssueCount></VolumeInfo><Issue IssueType="Regular" OutputMedium="All"><IssueInfo IssueType="Regular" TocLevels="0"><IssueIDStart>12</IssueIDStart><IssueIDEnd>12</IssueIDEnd><IssueArticleCount>18</IssueArticleCount><IssueHistory><OnlineDate><Year>2011</Year><Month>11</Month><Day>18</Day></OnlineDate><PrintDate><Year>2011</Year><Month>11</Month><Day>17</Day></PrintDate><CoverDate><Year>2011</Year><Month>12</Month></CoverDate><PricelistYear>2011</PricelistYear></IssueHistory><IssueCopyright><CopyrightHolderName>Clinical Rheumatology</CopyrightHolderName><CopyrightYear>2011</CopyrightYear></IssueCopyright></IssueInfo><Article ID="s10067-011-1775-5" OutputMedium="All"><ArticleInfo ArticleType="OriginalPaper" ContainsESM="No" Language="En" NumberingStyle="Unnumbered" TocLevels="0"><ArticleID>1775</ArticleID><ArticleDOI>10.1007/s10067-011-1775-5</ArticleDOI><ArticleSequenceNumber>10</ArticleSequenceNumber><ArticleTitle Language="En">Current smoking status is associated to a non-ACR 50 response in early rheumatoid arthritis. A cohort study</ArticleTitle><ArticleCategory>Original Article</ArticleCategory><ArticleFirstPage>1589</ArticleFirstPage><ArticleLastPage>1593</ArticleLastPage><ArticleHistory><RegistrationDate><Year>2011</Year><Month>5</Month><Day>7</Day></RegistrationDate><Received><Year>2010</Year><Month>9</Month><Day>10</Day></Received><Revised><Year>2011</Year><Month>4</Month><Day>6</Day></Revised><Accepted><Year>2011</Year><Month>5</Month><Day>6</Day></Accepted><OnlineDate><Year>2011</Year><Month>5</Month><Day>24</Day></OnlineDate></ArticleHistory><ArticleCopyright><CopyrightHolderName>Clinical Rheumatology</CopyrightHolderName><CopyrightYear>2011</CopyrightYear></ArticleCopyright><ArticleGrants Type="Regular"><MetadataGrant Grant="OpenAccess"></MetadataGrant><AbstractGrant Grant="OpenAccess"></AbstractGrant><BodyPDFGrant Grant="Restricted"></BodyPDFGrant><BodyHTMLGrant Grant="Restricted"></BodyHTMLGrant><BibliographyGrant Grant="Restricted"></BibliographyGrant><ESMGrant Grant="Restricted"></ESMGrant></ArticleGrants></ArticleInfo><ArticleHeader><AuthorGroup><Author AffiliationIDS="Aff1"><AuthorName DisplayOrder="Western"><GivenName>Jorge</GivenName><FamilyName>Rojas-Serrano</FamilyName></AuthorName><Contact><Email>jrojas@iner.gob.mx</Email></Contact></Author><Author AffiliationIDS="Aff2"><AuthorName DisplayOrder="Western"><GivenName>Leticia</GivenName><GivenName>Lino</GivenName><FamilyName>Pérez</FamilyName></AuthorName></Author><Author AffiliationIDS="Aff2"><AuthorName DisplayOrder="Western"><GivenName>Conrado</GivenName><GivenName>García</GivenName><FamilyName>García</FamilyName></AuthorName></Author><Author AffiliationIDS="Aff2"><AuthorName DisplayOrder="Western"><GivenName>Francisco</GivenName><FamilyName>Moctezuma</FamilyName></AuthorName></Author><Author AffiliationIDS="Aff2"><AuthorName DisplayOrder="Western"><GivenName>Everardo</GivenName><FamilyName>Álvarez-Hernández</FamilyName></AuthorName></Author><Author AffiliationIDS="Aff2 Aff3"><AuthorName DisplayOrder="Western"><GivenName>Janitzia</GivenName><FamilyName>Vázquez-Mellado</FamilyName></AuthorName></Author><Author AffiliationIDS="Aff4"><AuthorName DisplayOrder="Western"><GivenName>José</GivenName><GivenName>Luis</GivenName><FamilyName>Montiel</FamilyName></AuthorName></Author><Author AffiliationIDS="Aff2 Aff3" CorrespondingAffiliationID="Aff3"><AuthorName DisplayOrder="Western"><GivenName>Rubén</GivenName><FamilyName>Burgos-Vargas</FamilyName></AuthorName><Contact><Email>burgosv@prodigy.net.mx</Email></Contact></Author><Affiliation ID="Aff1"><OrgDivision>Instituto Nacional de Enfermedades Respiratorias, Ismael Cosío Villegas</OrgDivision><OrgName>Universidad Nacional Autónoma de México, Faculty of Medicine</OrgName><OrgAddress><City>Mexico City</City><Country Code="MX">Mexico</Country></OrgAddress></Affiliation><Affiliation ID="Aff2"><OrgDivision>Department of Rheumatology</OrgDivision><OrgName>Hospital General de México</OrgName><OrgAddress><City>Mexico City</City><Country Code="MX">Mexico</Country></OrgAddress></Affiliation><Affiliation ID="Aff3"><OrgName>Universidad Nacional Autónoma de México, Faculty of Medicine</OrgName><OrgAddress><City>Mexico City</City><Country Code="MX">Mexico</Country></OrgAddress></Affiliation><Affiliation ID="Aff4"><OrgName>Universidad Autónoma del Estado de Morelos, Facultad de Farmacia</OrgName><OrgAddress><City>Mexico City</City><Country Code="MX">Mexico</Country></OrgAddress></Affiliation></AuthorGroup><Abstract ID="Abs1" Language="En" OutputMedium="All"><Heading>Abstract</Heading><Para>The purpose of this study is to determine factors associated with a non-ACR 50 response at 6 months of follow-up, in a cohort of patients with early rheumatoid arthritis (RA). Early RA patients (symptom duration <1 year), treated with the same combination treatment (methotrexate and sulfasalazine), were included. Demographic characteristics of the patients including current smoker status (defined as a patient that smokes at least one cigarette per day), years of formal education, a 28-joint count for swelling and tenderness were registered. A basal HAQ questionnaire, visual scales for global assessment, and pain were answered by all patients, and a CDAI basal score was calculated. The ACR 50 response was determined at 6 months follow-up. Multivariable logistic regression analysis was used to calculate adjusted ORs. Two hundred twenty-five patients were evaluated, but only 144 had a complete follow-up, 43% of the latter did not reach an ACR 50 response. The only factor associated with this outcome was current smoking (OR 3.58, <Emphasis Type="Italic">P</Emphasis> < 0.008, 95% CI 1.23–11.22). Low level of formal education (≤6 years) had a tendency towards a statistical difference (<Emphasis Type="Italic">P</Emphasis> < 0.08). After controlling with low level of formal education, sex, age in years, and CDAI baseline value with multivariable logistic regression analysis, current smoking status had an adjusted OR of 3.91 (<Emphasis Type="Italic">P</Emphasis> < 0.009, 95% CI 1.41–10.81). Smoking is associated with a non-ACR 50 response in early rheumatoid arthritis in patients treated with a combination therapy with methotrexate and sulfasalazine.</Para></Abstract><KeywordGroup Language="En" OutputMedium="All"><Heading>Keywords</Heading><Keyword>Early rheumatoid arthritis</Keyword><Keyword>Methotrexate</Keyword><Keyword>Prognostic factors</Keyword><Keyword>Rheumatoid arthritis</Keyword><Keyword>Sulfasalazine</Keyword></KeywordGroup><ArticleNote Type="Misc"><SimplePara>This work was supported by grants of the CONACyT, SALUD-2007-01-71161, a Mexican agency supporting science.</SimplePara></ArticleNote></ArticleHeader><NoBody></NoBody></Article></Issue></Volume></Journal></Publisher></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Current smoking status is associated to a non-ACR 50 response in early rheumatoid arthritis. A cohort study</title></titleInfo><titleInfo type="alternative" contentType="CDATA"><title>Current smoking status is associated to a non-ACR 50 response in early rheumatoid arthritis. A cohort study</title></titleInfo><name type="personal"><namePart type="given">Jorge</namePart><namePart type="family">Rojas-Serrano</namePart><affiliation>Instituto Nacional de Enfermedades Respiratorias, Ismael Cosío Villegas, Universidad Nacional Autónoma de México, Faculty of Medicine, Mexico City, Mexico</affiliation><affiliation>E-mail: jrojas@iner.gob.mx</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Leticia</namePart><namePart type="given">Lino</namePart><namePart type="family">Pérez</namePart><affiliation>Department of Rheumatology, Hospital General de México, Mexico City, Mexico</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Conrado</namePart><namePart type="given">García</namePart><namePart type="family">García</namePart><affiliation>Department of Rheumatology, Hospital General de México, Mexico City, Mexico</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Francisco</namePart><namePart type="family">Moctezuma</namePart><affiliation>Department of Rheumatology, Hospital General de México, Mexico City, Mexico</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Everardo</namePart><namePart type="family">Álvarez-Hernández</namePart><affiliation>Department of Rheumatology, Hospital General de México, Mexico City, Mexico</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Janitzia</namePart><namePart type="family">Vázquez-Mellado</namePart><affiliation>Department of Rheumatology, Hospital General de México, Mexico City, Mexico</affiliation><affiliation>Universidad Nacional Autónoma de México, Faculty of Medicine, Mexico City, Mexico</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">José</namePart><namePart type="given">Luis</namePart><namePart type="family">Montiel</namePart><affiliation>Universidad Autónoma del Estado de Morelos, Facultad de Farmacia, Mexico City, Mexico</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal" displayLabel="corresp"><namePart type="given">Rubén</namePart><namePart type="family">Burgos-Vargas</namePart><affiliation>Department of Rheumatology, Hospital General de México, Mexico City, Mexico</affiliation><affiliation>Universidad Nacional Autónoma de México, Faculty of Medicine, Mexico City, Mexico</affiliation><affiliation>E-mail: burgosv@prodigy.net.mx</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="research-article" displayLabel="OriginalPaper" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-1JC4F85T-7">research-article</genre><originInfo><publisher>Springer-Verlag</publisher><place><placeTerm type="text">London</placeTerm></place><dateCreated encoding="w3cdtf">2010-09-10</dateCreated><dateIssued encoding="w3cdtf">2011-12-01</dateIssued><copyrightDate encoding="w3cdtf">2011</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><abstract lang="en">Abstract: The purpose of this study is to determine factors associated with a non-ACR 50 response at 6 months of follow-up, in a cohort of patients with early rheumatoid arthritis (RA). Early RA patients (symptom duration <1 year), treated with the same combination treatment (methotrexate and sulfasalazine), were included. Demographic characteristics of the patients including current smoker status (defined as a patient that smokes at least one cigarette per day), years of formal education, a 28-joint count for swelling and tenderness were registered. A basal HAQ questionnaire, visual scales for global assessment, and pain were answered by all patients, and a CDAI basal score was calculated. The ACR 50 response was determined at 6 months follow-up. Multivariable logistic regression analysis was used to calculate adjusted ORs. Two hundred twenty-five patients were evaluated, but only 144 had a complete follow-up, 43% of the latter did not reach an ACR 50 response. The only factor associated with this outcome was current smoking (OR 3.58, P < 0.008, 95% CI 1.23–11.22). Low level of formal education (≤6 years) had a tendency towards a statistical difference (P < 0.08). After controlling with low level of formal education, sex, age in years, and CDAI baseline value with multivariable logistic regression analysis, current smoking status had an adjusted OR of 3.91 (P < 0.009, 95% CI 1.41–10.81). Smoking is associated with a non-ACR 50 response in early rheumatoid arthritis in patients treated with a combination therapy with methotrexate and sulfasalazine.</abstract><note>Original Article</note><subject lang="en"><genre>Keywords</genre><topic>Early rheumatoid arthritis</topic><topic>Methotrexate</topic><topic>Prognostic factors</topic><topic>Rheumatoid arthritis</topic><topic>Sulfasalazine</topic></subject><relatedItem type="host"><titleInfo><title>Clinical Rheumatology</title><subTitle>Journal of the International League of Associations for Rheumatology</subTitle></titleInfo><titleInfo type="abbreviated"><title>Clin Rheumatol</title></titleInfo><genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre><originInfo><publisher>Springer</publisher><dateIssued encoding="w3cdtf">2011-11-18</dateIssued><copyrightDate encoding="w3cdtf">2011</copyrightDate></originInfo><subject><genre>Medicine & Public Health</genre><topic>Rheumatology</topic></subject><identifier type="ISSN">0770-3198</identifier><identifier type="eISSN">1434-9949</identifier><identifier type="JournalID">10067</identifier><identifier type="IssueArticleCount">18</identifier><identifier type="VolumeIssueCount">12</identifier><part><date>2011</date><detail type="volume"><number>30</number><caption>vol.</caption></detail><detail type="issue"><number>12</number><caption>no.</caption></detail><extent unit="pages"><start>1589</start><end>1593</end></extent></part><recordInfo><recordOrigin>Clinical Rheumatology, 2011</recordOrigin></recordInfo></relatedItem><identifier type="istex">32146B4C9F763382B0127713652689FEEA340BA6</identifier><identifier type="ark">ark:/67375/VQC-MVSBSK0P-P</identifier><identifier type="DOI">10.1007/s10067-011-1775-5</identifier><identifier type="ArticleID">1775</identifier><identifier type="ArticleID">s10067-011-1775-5</identifier><accessCondition type="use and reproduction" contentType="copyright">Clinical Rheumatology, 2011</accessCondition><recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-3XSW68JL-F">springer</recordContentSource><recordOrigin>Clinical Rheumatology, 2011</recordOrigin></recordInfo></mods><json:item><extension>json</extension><original>false</original><mimetype>application/json</mimetype><uri>https://api.istex.fr/ark:/67375/VQC-MVSBSK0P-P/record.json</uri></json:item></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001F05 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 001F05 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:32146B4C9F763382B0127713652689FEEA340BA6
|texte= Current smoking status is associated to a non-ACR 50 response in early rheumatoid arthritis. A cohort study
}}
| This area was generated with Dilib version V0.6.33. |  |